Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial-Reference-Cited by-同舟云学术

Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial

Published:2023-04 Issue:2 Volume:6 Page:151-159
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Golan Shay,Frumer Michael,Zohar Yarden,Rosenbaum Eli,Yakimov Maxim,Kedar Daniel,Margel David,Baniel Jack,Steinmetz Adam P.,Groshar David,Domachevsky Liran,Bernstine Hanna

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference37 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

2. Radical prostatectomy for high-risk prostate cancer;Yossepowitch;World J Urol,2008

3. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era;Stephenson;J Clin Oncol,2009

4. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study;Hofman;Lancet,2020

5. Mechanisms of cell killing response from low linear energy transfer (LET) radiation originating from 177Lu radioimmunotherapy targeting disseminated intraperitoneal tumor xenografts;Yong;Int J Mol Sci,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer;Nature Reviews Urology;2024-08-07

2. Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer;Cancers;2024-07-12

3. Treatment and Staging Intensification Strategies Associated with Radical Prostatectomy for High-Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel Approaches;Cancers;2024-07-05

4. Role of Lutetium Radioligand Therapy in Prostate Cancer;Cancers;2024-07-01

5. Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects;BMC Cancer;2024-04-11